New pricing principles applied in decision on orphan drugs

New pricing principles applied in decision on orphan drugs

Dela med dig av vår kunskap
Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedInEmail this to someone

In the latest newsletter from the International Law Office, Lindahl’s Jonas Löfgren, Annie Kabala and Natalie Tell provides an update on recent developments in Sweden which further increases pricing uncertainty for orphan drugs.

Read the article here

Also read:

Lindahl provides an update on difficult position for orphan drugs

Orphan drug denied reimbursement in health technology assessment